Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Kitano, Daisuke ^a   Chiku, Masaaki ^b   Li, Yuxin ^c   Okumura, Yasuo ^a   Fukamachi, Daisuke ^a   Takayama, Tadateru ^a   Hiro, Takafumi ^a,c   Saito, Satoshi ^b,c   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Keiai Hospital   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Acute coronary syndrome; Alpha glucosidase inhibitor; Endothelial function; Miglitol; Postprandial hyperglycemia; Reactive hyperemia peripheral arterial tonometry

Indexed keywords

GLUCOSE; MIGLITOL; 1 DEOXYNOJIRIMYCIN; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPEREMIA; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TONOMETRY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; COMPLICATION; MANOMETRY; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

1-DEOXYNOJIRIMYCIN; ACUTE CORONARY SYNDROME; AGED; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MANOMETRY; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84879035570     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-92     Document Type: Article

References (70)

1. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
2. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
3. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. 10.1056/NEJMoa0808431, 19092145, VADT Investigators.
4. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924. 10.2337/diacare.22.6.920, 10372242.
5. DECODE Study Group the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405. 10.1001/archinte.161.3.397, 11176766, DECODE Study Group.
6. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G, Borch-Johnsen K. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006, 13:555-561. 10.1097/01.hjr.0000183916.28354.69, 16874145.
7. Lambert J, Aarsen M, Donker AJ, Stehouwer CD. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996, 16:705-711. 10.1161/01.ATV.16.5.705, 8963729.
8. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998, 32:110-116. 10.1016/S0735-1097(98)00211-3, 9669257.
9. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000, 101:1773-1779. 10.1161/01.CIR.101.15.1773, 10769276.
10. Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, Ertl G, Bauersachs J. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J 2005, 19:591-593.
11. Azuma K, Kawamori R, Toyofuku Y, Kitahara Y, Sato F, Shimizu T, Miura K, Mine T, Tanaka Y, Mitsumata M, Watada H. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol 2006, 26:2275-2280. 10.1161/01.ATV.0000239488.05069.03, 16888238.
12. Mita T, Otsuka A, Azuma K, Uchida T, Ogihara T, Fujitani Y, Hirose T, Mitsumata M, Kawamori R, Watada H. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2007, 358:679-685. 10.1016/j.bbrc.2007.04.118, 17506980.
13. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998, 44:1799-1808.
14. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001, 104:503-516. 10.1016/S0092-8674(01)00238-0, 11239408.
15. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44:2137-2141. 10.1016/j.jacc.2004.08.062, 15582310.
16. Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977, 64:536-537. 10.1007/BF00483562, 927538.
17. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 1997, 47:734-745.
18. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012, 9:163-169. 10.1177/1479164112441524, 22508699.
19. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494. 10.1001/jama.290.4.486, 12876091.
20. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16. 10.1016/S0195-668X(03)00468-8, 14683737.
21. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006, 91:837-842.
22. Hirano M, Nakamura T, Obata JE, Fujioka D, Saito Y, Kawabata K, Watanabe K, Watanabe Y, Kugiyama K. Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes. Circ J 2012, 76:1452-1460. 10.1253/circj.CJ-11-1524, 22453003.
23. Minatoguchi S, Arai M, Uno Y, Kariya T, Nishida Y, Hashimoto K, Kawasaki M, Takemura G, Fujiwara T, Fujiwara H. A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits. Br J Pharmacol 1999, 128:1667-1672. 10.1038/sj.bjp.0702970, 1571807, 10588921.
24. Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, Mizuguchi T, Motodi Y, Iwasaki M, Taira K, Okamoto H, Matsuo Y, Kim SK, Takarada A, Yokoyama M. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2012, 109:42-46. 10.1016/j.amjcard.2011.08.005, 21944671.
25. Yoshino G, Tominaga M, Hirano M, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima M, Sanke T, Oikawa S, Honda K, Tachikawa T. The test meal A: A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Japan Diab Soc 2006, 49:361-371.
26. Yoshino G. Test meal A for the simultaneous assessment of postprandial hyperglycemia and hyperlipidemia in diabetic subjects. Jpn J Nutr Diet 2007, 65:105-112.
27. Yoshino G. Clinical application of test meal A. Diabetes-Journal 2008, 36:70-78.
28. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, Barsotti A, Terranova R, Nicolaides A. A simple test to monitor oxidative stress. Int Angiol 1999, 18(2):127-130.
29. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT, Schnall RP, Holmes DR, Higano ST, Lerman A. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003, 41:1761-1768. 10.1016/S0735-1097(03)00329-2, 12767662.
30. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008, 117:2467-2474. 10.1161/CIRCULATIONAHA.107.748574, 2734141, 18458169.
31. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732. 10.1016/j.jacc.2004.07.001, 15358046.
32. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78. 10.1136/bmj.38678.389583.7C, 1326926, 16371403.
33. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-171. 10.1161/CIRCULATIONAHA.106.179918, 17194875, American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
34. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999, 22:1262-1265. 10.2337/diacare.22.8.1262, 10480768.
35. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621.
36. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7. 10.2337/diabetes.54.1.1, 15616004.
37. Suzuki K, Watanabe K, Futami-Suda S, Yano H, Motoyama M, Matsumura N, Igari Y, Suzuki T, Nakano H, Oba K. The effects of postprandial glucose and insulin levels on postprandial endothelial function in subjects with normal glucose tolerance. Cardiovasc Diabetol 2012, 11:98. 10.1186/1475-2840-11-98, 3471039, 22891922.
38. Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol 2012, 11:79. 10.1186/1475-2840-11-79, 3492036, 22748110.
39. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32:381-386. 10.2337/dc08-1671, 2646013, 19246588.
40. Tofler GH, Stone PH, Maclure M, Edelman E, Davis VG, Robertson T, Antman EM, Muller JE. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 1990, 66:22-27. 10.1016/0002-9149(90)90729-K, 2193495.
41. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144. 10.1016/S0140-6736(02)09089-X, 12090978.
42. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009, 73:595-601. 10.1253/circj.CJ-08-1169, 19225203.
43. Inoue T, Matsuoka H, Higashi Y, Ueda S, Sata M, Shimada KE, Ishibashi Y, Node K. Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res 2008, 31:2105-2113. 10.1291/hypres.31.2105, 19139600.
44. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456. 10.1038/320454a0, 3007998.
45. Rubanyi GM, Vanhoutte PM. Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. Am J Physiol 1986, 250:H815-821.
46. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34:146-154. 10.1016/S0735-1097(99)00168-0, 10400004.
47. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 1995, 268:E1167-1173.
48. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T. Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 2011, 216:477-483. 10.1016/j.atherosclerosis.2011.02.033, 21414624.
49. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957. 10.1056/NEJM199604113341504, 8596596.
50. Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes 1996, 45(Suppl 3):S45-46.
51. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002, 105:576-582. 10.1161/hc0502.103333, 11827922.
52. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010, 9:12. 10.1186/1475-2840-9-12, 2861640, 20334663.
53. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954. 10.1161/01.CIR.101.9.948, 10704159.
54. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005, 111:363-368. 10.1161/01.CIR.0000153339.27064.14, 15668353.
55. Hamburg NM, Palmisano J, Larson MG, Sullivan LM, Lehman BT, Vasan RS, Levy D, Mitchell GF, Vita JA, Benjamin EJ. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension 2011, 57:390-396. 10.1161/HYPERTENSIONAHA.110.160812, 3049726, 21263120.
56. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 2006, 101:545-548. 10.1152/japplphysiol.01285.2005, 16614356.
57. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010, 31:1142-1148. 10.1093/eurheartj/ehq010, 20181680.
58. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M, Matsubara J, Sumida H, Kaikita K, Kojima S, Nagayoshi Y, Yamamuro M, Izumiya Y, Iwashita S, Matsui K, Jinnouchi H, Kimura K, Umemura S, Ogawa H. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol 2010, 55:1688-1696. 10.1016/j.jacc.2009.10.073, 20394872.
59. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000, 59:521-549. 10.2165/00003495-200059030-00012, 10776834.
60. Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, Fukushima Y, Kume A, Matsumori R, Sumiyoshi K, Miyazaki T, Ohmura H, Kurata T, Miida T, Daida H. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J 2010, 74:1471-1478. 10.1253/circj.CJ-10-0013, 20519875.
61. Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol 2011, 10:115. 10.1186/1475-2840-10-115, 3307032, 22189184.
62. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002, 4:329-335. 10.1046/j.1463-1326.2002.00219.x, 12190996.
63. Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, Yamada Y. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009, 26:187-188. 10.1111/j.1464-5491.2008.02651.x, 19236625.
64. Iwasa M, Yamada Y, Kobayashi H, Yasuda S, Kawamura I, Sumi S, Shiraki T, Yamaki T, Ushikoshi H, Hattori A, Aoyama T, Nishigaki K, Takemura G, Fujiwara H, Minatoguchi S. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol 2011, 164:119-131. 10.1111/j.1476-5381.2011.01357.x, 3171865, 21426318.
65. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010, 53:2256-2263. 10.1007/s00125-010-1831-8, 20593161.
66. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010, 33:1028-1030. 10.2337/dc09-1961, 2858168, 20200309.
67. von Bibra H, St John Sutton M. Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep 2011, 8:242-251. 10.1007/s11897-011-0070-8, 3208100, 21842146.
68. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K, Sugamura K, Yamamuro M, Sumida H, Kaikita K, Iwashita S, Matsui K, Kimura K, Umemura S, Ogawa H. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2012, 60(18):1778-1786. 10.1016/j.jacc.2012.07.036, 23040568.
69. AlZadjali MA, Godfrey V, Khan F, Choy A, Doney AS, Wong AK, Petrie JR, Struthers AD, Lang CC. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 2009, 53:747-753. 10.1016/j.jacc.2008.08.081, 19245964.
70. Enomoto K, Yamabe H, Toyama K, Matsuzawa Y, Yamamuro M, Uemura T, Morihisa K, Iwashita S, Kaikita K, Sugiyama S, Ogawa H. Improvement effect on endothelial function in patients with congestive heart failure treated with cardiac resynchronization therapy. J Cardiol 2011, 58(1):69-73. 10.1016/j.jjcc.2011.01.010, 21493043.